Table III.

Therapeutic agents previously described to upregulate the expression of CAR.

	Agent	Function	Source	Cancer type	Description	Ref.
Kitazono, 2001	FR901228	Histone deacetylase inhibitor	Depsipeptide fermentation product from Chromobacterium violaceum, first isolated by the Fujisawa Pharmaceutical Company, Ltd. (Osaka, Japan)	Carcinoma of thyroid, colon, renal cell, breast and hepatic cell	Increased CAR mRNA levels observed in all cell lines following 1 ng/ml for 72 h	(43)
Ma, 2012	TSA	Histone deacetylase inhibitor	Sigma-Aldrich (St. Louis, MO, USA)	Esophageal squamous cell carcinoma	CAR protein expression levels increased in a dose-dependent manner in EC1 cells following TSA treatment (0.3, 0.5 and 1.0 µmol/l)	(42)
Yoo, 2004	Docetaxel	G2M-arresting agent	Sanofi S.A. (Paris, France	Head and neck cancer	Docetaxel treatment (25 ng/ml for 24 h) increased the expression of CAR, analyzed by fluorescence-activated cell sorting, and resulted in increased adenoviral transduction rates	(44)

CAR, coxsackie and adenovirus receptor; TSA, trichostatin A.